Quick Hits: Guidelines Could Boost Use of Hypertension Meds, Using AI to Predict Drug Interactions & More

The FDA has approved the first topical treatment for excessive underarm sweating. The new medicated wipe — known as Qbrexza — was approved for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients 9 years of age and older. It works by blocking sweat production and can be applied once a day. The most common side effects observed during the use of Qbrexza in trials were dry mouth, dilated pupils, sore throat, headache, urinary hesitation, blurred vision, dry nose, dry throat, dry eye, dry skin and constipation. The most common local skin reactions were erythema, burning/stinging and pruritus. Posted June 29, 2018. Via Dermira.

Leave a Reply

Your email address will not be published. Required fields are marked *